Effects of resveratrol on heart health in postmenopausal women
The Effects of Resveratrol on Inhibitors of Apoptosis Proteins, on Soluble Receptors of Advanced Glycation End Products and on Sirtuins-1 and -3 in Postmenopausal Women With Coronary Artery Disease
This study is testing if taking resveratrol can improve heart health in postmenopausal women with stable coronary artery disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 55 Years and up |
| Sex | Female |
| Sponsor | InCor Heart Institute Academic / other |
| Locations | 1 site (São Paulo, São Paulo) |
| Trial ID | NCT05808387 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates how resveratrol, a natural compound, influences sirtuins and apoptosis biomarkers in postmenopausal women with stable coronary artery disease (CAD). It involves a randomized, double-blind, placebo-controlled design where participants will receive either 1000 mg of resveratrol or a placebo daily for 90 days. The study aims to assess changes in lipid and glucose metabolism, inflammatory biomarkers, and gene expression related to heart health. The focus is on understanding the potential protective effects of resveratrol against CAD in this specific population.
Who should consider this trial
Good fit: Ideal candidates for this study are postmenopausal women aged 55 and older who have been diagnosed with stable coronary artery disease and have a BMI between 25 and 35 kg/m2.
Not a fit: Patients with thyroid disorders, rheumatic diseases, liver or kidney failure, those on hormone replacement therapy, or using insulin may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new dietary intervention to improve heart health and reduce risks associated with coronary artery disease in postmenopausal women.
How similar studies have performed: While the specific approach of using resveratrol in this context may be novel, previous studies have indicated potential benefits of resveratrol in cardiovascular health.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Postmenopausal women; * Diagnosed coronary artery disease; * Stable coronary disease; Exclusion Criteria: * hypo or hyperthyroidism, * rheumatic disease, * use of alcohol, * hepatic failure, * renal failure * hormone replacement therapy * use of insulin
Where this trial is running
São Paulo, São Paulo
- INCOR- Heart Institute — São Paulo, São Paulo, Brazil (Recruiting)
Study contacts
- Principal investigator: Antonio P Mansur, PhD — InCor Heart Institute
- Study coordinator: Antonio P Mansur, PhD
- Email: apmansur@yahoo.com
- Phone: 551126615448
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.